CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-489

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review
Review for HFD-160

03 JUN 2003

NDA: 21-489

Drug Product Name
Proprietary: ProHance Multipak
Non-proprietary: gadoteridol injection
Drug Product Classification: imaging agent

Review Number: 1

Subject of this Review
Submission Date: 16 DEC 2002
Receipt Date: 17 DEC 2002
Consult Date: 19 DEC 2002
Date Assigned for Review: 7 JAN 2003

Submission History (for amendments only)
Date(s) of Previous Submission(s): N/A
Date(s) of Previous Micro Review(s): N/A

Applicant/Sponsor
Name: Bracco Diagnostics, Inc.
Address: 107 College Road East
Princeton, NJ 08540
Representative: Melanie Benson
Telephone: (609) 514-2254

Name of Reviewer: David Hussong

Conclusion: APPROVE

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUPPLEMENT:** N/A (new NDA)

2. **SUPPLEMENT PROVIDES FOR:** N/A

3. **MANUFACTURING SITE:**
Altana Pharma AG (formerly Byk Gulden Lomberg)
Robert Bosche Strasse 8
D-78224
Singen, Germany

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Pharmacy Bulk Package for intravenous injection. The solution is provided as a 50 mL fill in a 50 mL vial. The solution is formulated to have a strength of 279.3 mg/mL.

5. **METHOD(S) OF STERILIZATION:**
process

6. **PHARMACOLOGICAL CATEGORY:** Imaging agent

B. **SUPPORTING/RELATED DOCUMENTS:** NDA 20-131 (Prohance).

C. **REMARKS:** The submission provides for a new use of an existing formulation and packaging of an approved product. There are no manufacturing or packaging changes. New labeling describes the product's use as a pharmacy bulk package. Comments are provided in section, "G. Labeling" concerning the potential for confusion relating to the use of the name, "MultiPak."

filename: 21-489rev1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability - APPROVE

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – N/A (There are no changes to the manufacture of this product relative to the referenced, approved product (NDA 20-131). This product is sterilized by [redacted] process.

B. Brief Description of Microbiology Deficiencies – Comments are offered in the end of the labeling section, but these are not deficiencies. The experiment to demonstrate the product's ability to withstand a microbiological insult was not thoroughly documented. Additionally, the use of the name "MultiPak" seems misleading for a pharmacy bulk package.

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

III. Administrative

A. Reviewer's Signature _____

B. Endorsement Block
David Hussong/Microbiologist
Peter Cooney/Microbiology Supervisor

C. CC Block
cc:
Original NDA 21-489
HFD- 160/Division File/NDA 21-489

4 Page(s) Withheld

✓ § 552(b)(4) Trade Secret / Confidential

__ § 552(b)(5) Deliberative Process

__ § 552(b)(4) Draft Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Hussong
6/20/03 09:50:55 AM
MICROBIOLOGIST

Peter Cooney
6/20/03 09:55:45 AM
MICROBIOLOGIST